Healthcare provider profile · identity verified

Conor Mullin, MD

Family Practice · SOUTH HAVEN, MI · NPI 1013321983

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	286	118
Amlodipine Besylate	Amlodipine Besylate	143	56
Gabapentin	Gabapentin	129	37
Omeprazole	Omeprazole	122	45
Lisinopril	Lisinopril	120	47
Levothyroxine Sodium	Levothyroxine Sodium	110	50
Losartan Potassium	Losartan Potassium	100	37
Alprazolam	Alprazolam	80	21
Metoprolol Succinate	Metoprolol Succinate	79	33
Tramadol Hcl	Tramadol Hcl	79	27
Hydrochlorothiazide	Hydrochlorothiazide	76	30
Metformin Hcl	Metformin Hcl	68	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	22
Duloxetine Hcl	Duloxetine Hcl	64	22
Tamsulosin Hcl	Tamsulosin Hcl	61	22
Baclofen	Baclofen	55	27
Carvedilol	Carvedilol	51	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	23
Rosuvastatin Calcium	Rosuvastatin Calcium	48	20
Pantoprazole Sodium	Pantoprazole Sodium	47	24
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	21
Pravastatin Sodium	Pravastatin Sodium	43	18
Citalopram Hbr	Citalopram Hydrobromide	39	21
Albuterol Sulfate Hfa	Albuterol Sulfate	38	18
Alendronate Sodium	Alendronate Sodium	38	11
Trulicity	Dulaglutide	37	12
Diazepam	Diazepam	35	13
Trazodone Hcl	Trazodone Hcl	33	14
Meloxicam	Meloxicam	31	18
Furosemide	Furosemide	30	12
Ezetimibe	Ezetimibe	29	suppressed
Simvastatin	Simvastatin	29	14
Eliquis	Apixaban	28	12
Famotidine	Famotidine	28	12
Metformin Hcl Er	Metformin Hcl	28	15
Prednisone	Prednisone	27	23
Ozempic	Semaglutide	25	suppressed
Naproxen	Naproxen	23	13
Temazepam	Temazepam	23	suppressed
Testosterone Cypionate	Testosterone Cypionate	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Bupropion Xl	Bupropion Hcl	22	14
Nystatin	Nystatin	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Lorazepam	Lorazepam	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	13
Montelukast Sodium	Montelukast Sodium	19	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Buspirone Hcl	Buspirone Hcl	17	11
Jardiance	Empagliflozin	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Ranolazine Er	Ranolazine	17	suppressed
Sertraline Hcl	Sertraline Hcl	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	12
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Topiramate	Topiramate	13	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	11
Benazepril Hcl	Benazepril Hcl	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error